In line with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, ESTEVE is providing details of the Patient Organisations it partners with, including a description of the support and contributions made by year.
On July 10th, 2024, ESTEVE, a global pharmaceutical company headquartered in Barcelona, Spain, successfully completed the acquisition of HRA Pharma Rare Diseases, including HRA Pharma UK & Ireland Limited from Perrigo Company plc. This strategic move marks a milestone that heralds an exciting new chapter for our organization, as we join forces to enhance our capabilities in addressing rare and severe diseases.
Prior to the acquisition of HRA Pharma UK & Ireland by ESTEVE, HRA Pharma UK & Ireland is pleased to have provided support to the following Patient Organisations and charities from 2022 to 2024 inclusive:
Click here to learn more about the Methodological Note for Esteve's 2025 Report on Transfers of Value to Patient Organisations and Members of Public. View PDF
EST WEBSITE 2026-002 | June 2026
In 2024, ESTEVE provided £291.80 of monetary support to members of the public for their time and contribution to the production of educational materials for healthcare professionals.
Please note that the payments between Jan 2024 – and Mid-July were under the ownership of Perrigo Company PLC and then subsequently, following the acquisition by ESTEVE, under the ownership of Esteve RD UK & Ireland.
We have made the company decision to disclose the full year 2024 under HRA Pharma UK & Ireland Limited
Benelux 
France 
Germany 
Global 
Italy 
Portugal 
Spain 
Spain (CAT) 
